Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 14/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.56 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622268 | 1.00 | P2RY2 (0.62) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL5068300 | 0.98 | P2RY2 (0.63) | P2RY2P2RY6P2RY4P2RY14 | |
| Uridine SCHEMBL338288 | 0.91 | P2RY2 (0.65) | P2RY2P2RY6P2RY4P2RY14 | |
| Uridine SCHEMBL5875869 | 0.91 | P2RY2 (0.65) | P2RY2P2RY6P2RY4P2RY14 | |
| Uridine SCHEMBL5875823 | 0.91 | P2RY2 (0.65) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL4779843 | 0.89 | P2RY2 (0.55) | P2RY2P2RY6P2RY4 | |
| SCHEMBL2800171 | 0.88 | P2RY2 (0.61) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL622266 | 0.88 | P2RY2 (0.54) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL2167291 | 0.87 | P2RY2 (0.62) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL607048 | 0.87 | P2RY2 (0.62) | P2RY2P2RY6P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012019437-A1 | BLADDER CANCER TUMOR MARKER, ANTIBIOTIC AND APPLICATION THEREOF | 中国科学院生物物理研究所 (CN) | 2012-02-16 | — | — | WO | claimed |
| US-9073995-B2 | Bladder cancer tumor marker, antibody and use thereof | INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2015-07-07 | — | — | US | disclosed |
| US-20130164216-A1 | BLADDER CANCER TUMOR MARKER, ANTIBODY AND USE THEREOF | INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2013-06-27 | — | — | US | disclosed |
| WO-2012019437-A1 | BLADDER CANCER TUMOR MARKER, ANTIBIOTIC AND APPLICATION THEREOF | 中国科学院生物物理研究所 (CN) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164216-A1 | BLADDER CANCER TUMOR MARKER, ANTIBODY AND USE THEREOF | B4GALT1, GALNT3, CSGALNACT1 | P2RY2 2680/4885P2RY6 3894/4885P2RY4 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.